nach oben

European Journal of Nuclear Medicine and Molecular Imaging

Erschienen in:

06.06.2022 | Editorial

State-of-the-art of nuclear medicine and molecular imaging in China: after the first 66 years (1956–2022)

verfasst von: Xiaoli Lan, Li Huo, Shuren Li, Jing Wang, Weibo Cai

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Ausgabe 8/2022

Einloggen, um Zugang zu erhalten

Excerpt

This is a historical event. The five of us (Xiaoli Lan, Li Huo, Shuren Li, Jing Wang, and Weibo Cai) are thrilled and extremely proud to announce the publication of a European Journal of Nuclear Medicine and Molecular Imaging (EJNMMI) special issue entitled “State-of-the-Art of Nuclear Medicine and Molecular Imaging in China: After the First 66 Years (1956–2022)”, thanks to the tremendous support from the Editor-in-Chief of EJNMMI, Prof. Arturo Chiti from Humanitas University in Milan, Italy. With a total of more than 40 articles, including review articles, research articles, and this editorial, we sincerely hope this special issue will be a good snapshot in time of the State-of-the-Art of Nuclear Medicine and Molecular Imaging in China, which has witnessed exceptional growth and development over the last several decades. We are truly grateful to all the authors, reviewers, editors, patients, and EJNMMI editorial staff for their invaluable contribution of time and expertise, and we are convinced that this special issue will be very well-received by readers in Europe and China, as well as around the world. …

Lane HC, Fauci AS. Research in the context of a pandemic. N Engl J Med. 2021;384:755–7. https://doi.org/10.1056/NEJMe2024638.CrossRefPubMed

Neuzil KM. Interplay between emerging SARS-CoV-2 variants and pandemic control. N Engl J Med. 2021;384:1952–4. https://doi.org/10.1056/NEJMe2103931.CrossRefPubMed

Wang SC, Chou CE. A brief overview of nuclear medicine in China. Semin Nucl Med. 1989;19:144–51. https://doi.org/10.1016/s0001-2998(89)80008-x.CrossRefPubMed

Hu J, Li H, Sui Y, Du J (2021) Current status and future perspective of radiopharmaceuticals in China. Eur J Nucl Med Mol Imaging. 1–17. https://doi.org/10.1007/s00259-021-05615-6.

Badawi RD, Shi H, Hu P, Chen S, Xu T, Price PM, et al. First Human Imaging Studies with the EXPLORER Total-Body PET Scanner. J Nucl Med. 2019;60:299–303. https://doi.org/10.2967/jnumed.119.226498.CrossRefPubMedPubMedCentral

Song W, Song Y, Li Q, Fan C, Lan X, Jiang D. Advances in aptamer-based nuclear imaging. Eur J Nucl Med Mol Imaging. 2022. https://doi.org/10.1007/s00259-022-05782-0.CrossRefPubMed

Li P, He X, Li Y, Lam JWY, Kwok RTK, Wang CC, et al. Recent advances in aggregation-induced emission luminogens in photoacoustic imaging. Eur J Nucl Med Mol Imaging. 2022. https://doi.org/10.1007/s00259-022-05726-8.CrossRefPubMedPubMedCentral

Zhang Z, He K, Chi C, Hu Z, Tian J. Intraoperative fluorescence molecular imaging accelerates the coming of precision surgery in China. Eur J Nucl Med Mol Imaging. 2022. https://doi.org/10.1007/s00259-022-05730-y.CrossRefPubMedPubMedCentral

Shi Z, Zhang Z, Liu Z, Zhao L, Ye Z, Dekker A, et al. Methodological quality of machine learning-based quantitative imaging analysis studies in esophageal cancer: a systematic review of clinical outcome prediction after concurrent chemoradiotherapy. Eur J Nucl Med Mol Imaging. 2021. https://doi.org/10.1007/s00259-021-05658-9.CrossRefPubMedPubMedCentral

10.

Li M, Younis MH, Zhang Y, Cai W, Lan X. Clinical summary of fibroblast activation protein inhibitor-based radiopharmaceuticals: cancer and beyond. Eur J Nucl Med Mol Imaging. 2022. https://doi.org/10.1007/s00259-022-05706-y.CrossRefPubMedPubMedCentral

11.

Huang Z, Wu Y, Fu F, Meng N, Gu F, Wu Q, et al. Parametric image generation with the uEXPLORER total-body PET/CT system through deep learning. Eur J Nucl Med Mol Imaging. 2022. https://doi.org/10.1007/s00259-022-05731-x.CrossRefPubMedPubMedCentral

12.

Liu G, Yu H, Shi D, Hu P, Hu Y, Tan H, et al. Short-time total-body dynamic PET imaging performance in quantifying the kinetic metrics of (18)F-FDG in healthy volunteers. Eur J Nucl Med Mol Imaging. 2021. https://doi.org/10.1007/s00259-021-05500-2.CrossRefPubMedPubMedCentral

13.

Zhang Y, Hu P, He Y, Yu H, Tan H, Liu G, et al. Ultrafast 30-s total-body PET/CT scan: a preliminary study. Eur J Nucl Med Mol Imaging. 2022. https://doi.org/10.1007/s00259-022-05838-1.CrossRefPubMedPubMedCentral

14.

Zhang Y, Cheng H, Chen H, Xu P, Ren E, Jiang Y, et al. A pure nanoICG-based homogeneous lipiodol formulation: toward precise surgical navigation of primary liver cancer after long-term transcatheter arterial embolization. Eur J Nucl Med Mol Imaging. 2021. https://doi.org/10.1007/s00259-021-05654-z.CrossRefPubMedPubMedCentral

15.

Xu J, Cai F, Luo Z, Fan W, Dai J, Cui J, et al. Design, synthesis, and preclinical evaluation of a novel bifunctional macrocyclic chelator for theranostics of cancers. Eur J Nucl Med Mol Imaging. 2022. https://doi.org/10.1007/s00259-022-05750-8.CrossRefPubMedPubMedCentral

16.

Hu G, Zhu W, Liu Y, Wang Y, Zhang Z, Zhu S, et al (2022) Development and comparison of three (89)Zr-labeled anti-CLDN18.2 antibodies to noninvasively evaluate CLDN18.2 expression in gastric cancer: a preclinical study. Eur J Nucl Med Mol Imaging. https://doi.org/10.1007/s00259-022-05739-3.

17.

Huang L, Fang J, Hong S, Liu H, Zhu H, Feng L, et al. MicroPET imaging of bacterial infection with nitroreductase-specific responsive (18)F-labelled nitrogen mustard analogues. Eur J Nucl Med Mol Imaging. 2022. https://doi.org/10.1007/s00259-022-05710-2.CrossRefPubMedPubMedCentral

18.

Hou Z, Zhou M, Ma Y, Xu X, Zhang Z, Lai S, et al. Size-changeable nanoprobes for the combined radiotherapy and photodynamic therapy of tumor. Eur J Nucl Med Mol Imaging. 2022. https://doi.org/10.1007/s00259-022-05830-9.CrossRefPubMedPubMedCentral

19.

Qian R, Jing B, Jiang D, Gai Y, Zhu Z, Huang X, et al. Multi-antitumor therapy and synchronous imaging monitoring based on exosome. Eur J Nucl Med Mol Imaging. 2022. https://doi.org/10.1007/s00259-022-05696-x.CrossRefPubMed

20.

An S, Zhang D, Zhang Y, Wang C, Shi L, Wei W, et al. GPC3-targeted immunoPET imaging of hepatocellular carcinomas. Eur J Nucl Med Mol Imaging. 2022. https://doi.org/10.1007/s00259-022-05723-x.CrossRefPubMed

21.

Xu H, Wang Y, Zhang J, Duan X, Zhang T, Cai X, et al. A self-triggered radioligand therapy agent for fluorescence imaging of the treatment response in prostate cancer. Eur J Nucl Med Mol Imaging. 2022. https://doi.org/10.1007/s00259-022-05743-7.CrossRefPubMedPubMedCentral

22.

Li H, Ye S, Li L, Zhong J, Yan Q, Zhong Y, et al. (18)F- or (177)Lu-labeled bivalent ligand of fibroblast activation protein with high tumor uptake and retention. Eur J Nucl Med Mol Imaging. 2022. https://doi.org/10.1007/s00259-022-05757-1.CrossRefPubMedPubMedCentral

23.

Yu F, Li M, Wang Q, Wang J, Wu S, Zhou R, et al. Spatiotemporal dynamics of brain function during the natural course in a dental pulp injury model. Eur J Nucl Med Mol Imaging. 2022. https://doi.org/10.1007/s00259-022-05764-2.CrossRefPubMed

24.

Wang G, Li W, Shi G, Tian Y, Kong L, Ding N, et al. Sensitive and specific detection of breast cancer lymph node metastasis through dual-modality magnetic particle imaging and fluorescence molecular imaging: a preclinical evaluation. Eur J Nucl Med Mol Imaging. 2022. https://doi.org/10.1007/s00259-022-05834-5.CrossRefPubMedPubMedCentral

25.

Wang X, Zhou M, Chen B, Liu H, Fang J, Xiang S, et al (2022) Preclinical and exploratory human studies of novel (68)Ga-labeled D-peptide antagonist for PET imaging of TIGIT expression in cancers. Eur J Nucl Med Mol Imaging. 1–11. https://doi.org/10.1007/s00259-021-05672-x.

26.

Fu Z, Lin Q, Xu Z, Zhao Y, Cheng Y, Shi D, et al. P2X7 receptor-specific radioligand (18)F-FTTM for atherosclerotic plaque PET imaging. Eur J Nucl Med Mol Imaging. 2022. https://doi.org/10.1007/s00259-022-05689-w.CrossRefPubMed

27.

Luo H, Yang C, Kuang D, Shi S, Chan AW. Visualizing dynamic changes in PD-L1 expression in non-small cell lung carcinoma with radiolabeled recombinant human PD-1. Eur J Nucl Med Mol Imaging. 2022. https://doi.org/10.1007/s00259-022-05680-5.CrossRefPubMed

28.

Lu D, Zhou H, Li N, Wang Y, Zhang T, Wang F, et al. Galectin expression detected by (68)Ga-galectracer PET as a predictive biomarker of radiotherapy resistance. Eur J Nucl Med Mol Imaging. 2022. https://doi.org/10.1007/s00259-022-05711-1.CrossRefPubMed

29.

Wei Y, Zheng J, Ma L, Liu X, Xu S, Wang S, et al. [(18)F]AlF-NOTA-FAPI-04: FAP-targeting specificity, biodistribution, and PET/CT imaging of various cancers. Eur J Nucl Med Mol Imaging. 2022. https://doi.org/10.1007/s00259-022-05758-0.CrossRefPubMed

30.

Wu Y, Zhang X, Zhou H, Xu B, Tian J, Sun S, et al. Synthesis, preclinical evaluation, and first-in-human study of Al(18)F-PSMA-Q for prostate cancer imaging. Eur J Nucl Med Mol Imaging. 2022. https://doi.org/10.1007/s00259-022-05775-z.CrossRefPubMedPubMedCentral

31.

Wang J, Yang H, Cui B, Shan B, Lu J. Effects of MRI protocols on brain FDG uptake in simultaneous PET/MR imaging. Eur J Nucl Med Mol Imaging. 2022. https://doi.org/10.1007/s00259-022-05703-1.CrossRefPubMedPubMedCentral

32.

Zhao Y, Wu P, Wu J, Brendel M, Lu J, Ge J, et al. Decoding the dopamine transporter imaging for the differential diagnosis of parkinsonism using deep learning. Eur J Nucl Med Mol Imaging. 2022. https://doi.org/10.1007/s00259-022-05804-x.CrossRefPubMed

33.

Xie B, Wang J, Xi XY, Guo X, Chen BX, Li L, et al. Fibroblast activation protein imaging in reperfused ST-elevation myocardial infarction: comparison with cardiac magnetic resonance imaging. Eur J Nucl Med Mol Imaging. 2022. https://doi.org/10.1007/s00259-021-05674-9.CrossRefPubMed

34.

Wu J, Tian J, Zhang Y, Ji H, Sun J, Wang X, et al. (18)F-Alfatide II for the evaluation of axillary lymph nodes in breast cancer patients: comparison with (18)F-FDG. Eur J Nucl Med Mol Imaging. 2022. https://doi.org/10.1007/s00259-021-05333-z.CrossRefPubMedPubMedCentral

35.

Zhang Z, Jia G, Pan G, Cao K, Yang Q, Meng H, et al. Comparison of the diagnostic efficacy of (68) Ga-FAPI-04 PET/MR and (18)F-FDG PET/CT in patients with pancreatic cancer. Eur J Nucl Med Mol Imaging. 2022. https://doi.org/10.1007/s00259-022-05729-5.CrossRefPubMedPubMedCentral

36.

Gu B, Liu X, Wang S, Xu X, Liu X, Hu S, et al. Head-to-head evaluation of [(18)F]FDG and [(68) Ga]Ga-DOTA-FAPI-04 PET/CT in recurrent soft tissue sarcoma. Eur J Nucl Med Mol Imaging. 2022. https://doi.org/10.1007/s00259-022-05700-4.CrossRefPubMedPubMedCentral

37.

Jiang C, Li A, Teng Y, Huang X, Ding C, Chen J, et al. Optimal PET-based radiomic signature construction based on the cross-combination method for predicting the survival of patients with diffuse large B-cell lymphoma. Eur J Nucl Med Mol Imaging. 2022. https://doi.org/10.1007/s00259-022-05717-9.CrossRefPubMed

38.

Sun K, Shi L, Qiu J, Pan Y, Wang X, Wang H. Multi-phase contrast-enhanced magnetic resonance image-based radiomics-combined machine learning reveals microscopic ultra-early hepatocellular carcinoma lesions. Eur J Nucl Med Mol Imaging. 2022. https://doi.org/10.1007/s00259-022-05742-8.CrossRefPubMedPubMedCentral

39.

He K, Li P, Zhang Z, Liu J, Liu P, Gong S, et al. Intraoperative near-infrared fluorescence imaging can identify pelvic nerves in patients with cervical cancer in real time during radical hysterectomy. Eur J Nucl Med Mol Imaging. 2022. https://doi.org/10.1007/s00259-022-05686-z.CrossRefPubMed

40.

Chen X, Liu X, Wang L, Zhou W, Zhang Y, Tian Y, et al. Expression of fibroblast activation protein in lung cancer and its correlation with tumor glucose metabolism and histopathology. Eur J Nucl Med Mol Imaging. 2022. https://doi.org/10.1007/s00259-022-05754-4.CrossRefPubMedPubMedCentral

41.

Yang G, Nie P, Yan L, Zhang M, Wang Y, Zhao L, et al. The radiomics-based tumor heterogeneity adds incremental value to the existing prognostic models for predicting outcome in localized clear cell renal cell carcinoma: a multicenter study. Eur J Nucl Med Mol Imaging. 2022. https://doi.org/10.1007/s00259-022-05773-1.CrossRefPubMedPubMedCentral

42.

Lin R, Lin Z, Chen Z, Zheng S, Zhang J, Zang J, et al. [(68)Ga]Ga-DOTA-FAPI-04 PET/CT in the evaluation of gastric cancer: comparison with [(18)F]FDG PET/CT. Eur J Nucl Med Mol Imaging. 2022. https://doi.org/10.1007/s00259-022-05799-5.CrossRefPubMed

43.

Zhao X, Liang YJ, Zhang X, Wen DX, Fan W, Tang LQ, et al. Deep learning signatures reveal multiscale intratumor heterogeneity associated with biological functions and survival in recurrent nasopharyngeal carcinoma. Eur J Nucl Med Mol Imaging. 2022. https://doi.org/10.1007/s00259-022-05793-x.CrossRefPubMed

44.

Zhou X, Wang S, Xu X, Meng X, Zhang H, Zhang A, et al. Higher accuracy of [(68) Ga]Ga-DOTA-FAPI-04 PET/CT comparing with 2-[(18)F]FDG PET/CT in clinical staging of NSCLC. Eur J Nucl Med Mol Imaging. 2022. https://doi.org/10.1007/s00259-022-05818-5.CrossRefPubMedPubMedCentral

45.

Sun T, Wang Z, Wu Y, Gu F, Li X, Bai Y, et al (2022) Identifying the individual metabolic abnormities from a systemic perspective using whole-body PET imaging. Eur J Nucl Med Mol Imaging. 1–11. https://doi.org/10.1007/s00259-022-05832-7.

46.

Qiu DX, Li J, Zhang JW, Chen MF, Gao XM, Tang YX, et al. Dual-tracer PET/CT-targeted, mpMRI-targeted, systematic biopsy, and combined biopsy for the diagnosis of prostate cancer: a pilot study. Eur J Nucl Med Mol Imaging. 2021. https://doi.org/10.1007/s00259-021-05636-1.CrossRefPubMed

47.

Hu K, Wang L, Wu H, Huang S, Tian Y, Wang Q, et al. [(18)F]FAPI-42 PET imaging in cancer patients: optimal acquisition time, biodistribution, and comparison with [(68)Ga]Ga-FAPI-04. Eur J Nucl Med Mol Imaging. 2021. https://doi.org/10.1007/s00259-021-05646-z.CrossRefPubMedPubMedCentral

48.

Qin X, Jiang H, Liu Y, Zhang H, Tian M. Radionuclide imaging of apoptosis for clinical application. Eur J Nucl Med Mol Imaging. 2022;49:1345–59. https://doi.org/10.1007/s00259-021-05641-4.CrossRefPubMed

49.

Xie B, Ding YF, Shui M, Yue L, Gao C, Wyman IW, et al. Supramolecular biomaterials for bio-imaging and imaging-guided therapy. Eur J Nucl Med Mol Imaging. 2022;49:1200–10. https://doi.org/10.1007/s00259-021-05622-7.CrossRefPubMed

50.

Duan X, Cao Z, Zhu H, Liu C, Zhang X, Zhang J, et al. (68)Ga-labeled ODAP-Urea-based PSMA agents in prostate cancer: first-in-human imaging of an optimized agent. Eur J Nucl Med Mol Imaging. 2022;49:1030–40. https://doi.org/10.1007/s00259-021-05486-x.CrossRefPubMed

51.

Zhu W, Jia R, Yang Q, Cheng Y, Zhao H, Bai C, et al. A prospective randomized, double-blind study to evaluate the diagnostic efficacy of (68)Ga-NODAGA-LM3 and (68)Ga-DOTA-LM3 in patients with well-differentiated neuroendocrine tumors: compared with (68)Ga-DOTATATE. Eur J Nucl Med Mol Imaging. 2022;49:1613–22. https://doi.org/10.1007/s00259-021-05512-y.CrossRefPubMed

52.

Kang L, Li C, Yang Q, Sutherlin L, Wang L, Chen Z, et al. (64)Cu-labeled daratumumab F(ab’)(2) fragment enables early visualization of CD38-positive lymphoma. Eur J Nucl Med Mol Imaging. 2022;49:1470–81. https://doi.org/10.1007/s00259-021-05593-9.CrossRefPubMed

53.

Zhang P, Xu M, Ding J, Chen J, Zhang T, Huo L, et al. Fatty acid-conjugated radiopharmaceuticals for fibroblast activation protein-targeted radiotherapy. Eur J Nucl Med Mol Imaging. 2022;49:1985–96. https://doi.org/10.1007/s00259-021-05591-x.CrossRefPubMed

54.

Wang G, Hong H, Zang J, Liu Q, Jiang Y, Fan X, et al. Head-to-head comparison of [(68) Ga]Ga-P16-093 and [(68) Ga]Ga-PSMA-617 in dynamic PET/CT evaluation of the same group of recurrent prostate cancer patients. Eur J Nucl Med Mol Imaging. 2022;49:1052–62. https://doi.org/10.1007/s00259-021-05539-1.CrossRefPubMed

55.

Guo K, Wang J, Wang Z, Wang Y, Cui B, Zhao G, et al. Morphometric analysis program and quantitative positron emission tomography in presurgical localization in MRI-negative epilepsies: a simultaneous PET/MRI study. Eur J Nucl Med Mol Imaging. 2022;49:1930–8. https://doi.org/10.1007/s00259-021-05657-w.CrossRefPubMed

56.

Zhao L, Pang Y, Wang Y, Chen J, Zhuang Y, Zhang J, et al. Somatostatin receptor imaging with [(68)Ga]Ga-DOTATATE positron emission tomography/computed tomography (PET/CT) in patients with nasopharyngeal carcinoma. Eur J Nucl Med Mol Imaging. 2022;49:1360–73. https://doi.org/10.1007/s00259-021-05587-7.CrossRefPubMed

57.

Shi J, Xue Z, Tan KV, Yuan H, Tsang ACM, Tsao SW, et al. Longitudinal evaluation of five nasopharyngeal carcinoma animal models on the microPET/MR platform. Eur J Nucl Med Mol Imaging. 2022;49:1497–507. https://doi.org/10.1007/s00259-021-05633-4.CrossRefPubMed

58.

Liu T, Wu Y, Shi L, Li L, Hu B, Wang Y, et al. Preclinical evaluation of [(99m)Tc]Tc-labeled anti-EpCAM nanobody for EpCAM receptor expression imaging by immuno-SPECT/CT. Eur J Nucl Med Mol Imaging. 2022;49:1810–21. https://doi.org/10.1007/s00259-021-05670-z.CrossRefPubMed

59.

Wen X, Shi C, Yang L, Zeng X, Lin X, Huang J, et al. A radioiodinated FR-β-targeted tracer with improved pharmacokinetics through modification with an albumin binder for imaging of macrophages in AS and NAFL. Eur J Nucl Med Mol Imaging. 2022;49:503–16. https://doi.org/10.1007/s00259-021-05447-4.CrossRefPubMed

60.

Wang S, Zhou X, Xu X, Ding J, Liu S, Hou X, et al. Clinical translational evaluation of Al(18)F-NOTA-FAPI for fibroblast activation protein-targeted tumour imaging. Eur J Nucl Med Mol Imaging. 2021;48:4259–71. https://doi.org/10.1007/s00259-021-05470-5.CrossRefPubMed

61.

Liu T, Liu C, Zhang Z, Zhang N, Guo X, Xia L, et al. (64)Cu-PSMA-BCH: a new radiotracer for delayed PET imaging of prostate cancer. Eur J Nucl Med Mol Imaging. 2021;48:4508–16. https://doi.org/10.1007/s00259-021-05426-9.CrossRefPubMed

62.

Zhang Z, Chen X, Wan Q, Wang H, Qi N, You Z, et al. A two-stage cardiac PET and late gadolinium enhancement MRI co-registration method for improved assessment of non-ischemic cardiomyopathies using integrated PET/MR. Eur J Nucl Med Mol Imaging. 2022. https://doi.org/10.1007/s00259-022-05681-4.CrossRefPubMedPubMedCentral

63.

Younis MH, Malih S, Lan X, Rasaee MJ, Cai W. Enhancing fibroblast activation protein (FAP)-targeted radionuclide therapy with albumin binding, and beyond. Eur J Nucl Med Mol Imaging. 2022;49:1773–7. https://doi.org/10.1007/s00259-022-05766-0.CrossRefPubMed

64.

China Nuclear Imaging Market - growth, trends, and forecasts (2020 - 2025): mordor Intelligence; 2020.

Titel: State-of-the-art of nuclear medicine and molecular imaging in China: after the first 66 years (1956–2022)
verfasst von: Xiaoli Lan
Li Huo
Shuren Li
Jing Wang
Weibo Cai
Publikationsdatum: 06.06.2022
Verlag: Springer Berlin Heidelberg
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe 8/2022
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-022-05856-z

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

State-of-the-art of nuclear medicine and molecular imaging in China: after the first 66 years (1956–2022)

Excerpt

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 8/2022

18F- or 177Lu-labeled bivalent ligand of fibroblast activation protein with high tumor uptake and retention

[68Ga]Ga-DOTA-FAPI-04 PET/CT in the evaluation of gastric cancer: comparison with [18F]FDG PET/CT

Parametric image generation with the uEXPLORER total-body PET/CT system through deep learning

Higher accuracy of [68 Ga]Ga-DOTA-FAPI-04 PET/CT comparing with 2-[18F]FDG PET/CT in clinical staging of NSCLC

Sensitive and specific detection of breast cancer lymph node metastasis through dual-modality magnetic particle imaging and fluorescence molecular imaging: a preclinical evaluation

Deep learning signatures reveal multiscale intratumor heterogeneity associated with biological functions and survival in recurrent nasopharyngeal carcinoma